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ABSTRACT
In a multicenter, randomized, investigator-blind, parallel study, 398 patients were dispensed topical
butoconazole nitrate 2% cream for 3 days (n 199) or miconazole nitrate 2% cream for 7 days (n
199) for vaginal use. Efficacy analyses included 254 patients with culture-confirmed Candida (119
butoconazole and 135 miconazole users). Of the 398 patients issued study medication, 9 were lost
to follow-up. Therefore, safety analyses included 389 patients (197 butoconazole and 192 micona-
zole users). Evaluations upon admission and approximately 8 and 30 days post-treatment included
Candida cultures, potassium hydroxide (KOH) wet mounts, and vulvovaginal examinations, with
rating of vulvovaginal signs and symptoms using a 4-point scale. Rates of clinical cure (based on
sign/symptom scores), microbiologic cure (based on cultures and wet mounts), and therapeutic cure
(both clinical and microbiologic cures) were assessed and were to be similar between the regimens.
Therapeutic cure rates were 57.8% and 61.4% for butoconazole and miconazole, respectively.
Three-day butoconazole treatment was as safe and effective as 7-day miconazole therapy in treat-
ing vulvovaginal candidiasis. Infect. Dis. Obstet. Gynecol. 4:323-328, 1996. (C) 1997 Wiley-Liss, Inc.
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utoconazole nitrate 2% cream and miconazole
}nitrate 2% cream have both been used as ef-
fective intravaginal antifungal agents to treat vul-
vovaginal candidiasis, one of the most common gy-
necological problems. 1,e
It is important for women who are first-time suf-
ferers to consult their physicians before using any
over-the-counter products to treat vulvovaginal
candidiasis, thus ensuring an accurate diagnosis.
With the diagnosis of vulvovaginal candidiasis
comes the challenge to health care professionals of
patient compliance. Several factors may influence
compliance, including length of antifungal therapy.
To that end, physician recommendations which
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encourage compliance may include short-term an-
tifungal therapy.3,4
The primary objective of this study was to com-
pare the effectiveness and safety of 3-day buto-
conazole with 7-day miconazole treatments in
women with vulvovaginal candidiasis. Therapeutic,
microbiologic, and clinical cure rates were deter-
mined after consecutive daily intravaginal treat-
ment with either butoconazole nitrate 2% cream (3
days) or miconazole nitrate 2% cream (7 days).
SUBJECTS AND METHODS
The study had a multicenter, randomized, investi-
gator-blind, parallel design. Eligible patients were
randomly assigned to treatment once daily at bed-
time with either butoconazole nitrate cream for 3
consecutive days or miconazole nitrate cream for 7
consecutive days. Butoconazole nitrate was pre-
sented to patients in one box containing 3 applica-
tors prefilled with butoconazole nitrate cream. Mi-
conazole nitrate was presented to patients in one
box containing 7 applicators and a tube of’micona-
zole cream. Boxes were identically packaged.
Admission Criteria
Patients admitted to the trial were generally
healthy women with pseudohyphae on potassium
hydroxide (KOH) wet mount, which was con-
firmed by a positive Candida culture. Enrolled pa-
tients signed an informed consent and agreed to
abstain from sexual intercourse during the treat-
ment period and to use condoms for the remainder
of the study period. During the study they also
agreed to abstain from using any vaginal product
containing nonoxynol-9, vaginal douches, other
vaginal or vulvar topical therapeutics, vaginal con-
traceptives, or feminine sprays. Excluded from the
study were patients with evidence of trichomonads
or clue cells (indicative of bacterial vaginosis); vul-
var, cervical, or vaginal lesions other than candidi-
asis (e.g., herpes); diabetes mcllitus, acquired im-
munodeficienc syndrome (AIDS), or any uncon-
trolled systemic disease; and urinary tract infection
or any genitourinary condition including sexually
transmitted disease. Candidates were also ex-
cluded if they were pregnant or breast-feeding; had
been treated for vulvovaginal candidiasis within
the week preceding study entry; had used any vagi-
nal preparations within 24 h before study entry;
were receiving anti-inflammatory, antihistamine, or
analgesic drugs on an ongoing basis; or would re-
quire oral antibiotics during the study treatment.
Assessments
Patients had an admission visit and two follow-up
visits scheduled as close as possible to 8 and 30
days after the end of treatment. At the admission
visit, a medical history was obtained and a physical
including vulvovaginal examination was per-
formed. Vulvovaginal signs (erythema, swelling,
excoriation, ulceration) and symptoms (burning,
itching) were recorded and rated on a 4-point scale
(0 none; mild; 2 moderate; 3 severe). Each
patient had a sodium chloride and KOH wet
mount, Candida yeast culture (including species
identification) to confirm the presence of Candida,
Pap smear (if not done within the previous 6
months), urine pregnancy test (if the patient was of
child-bearing potential), and urinalysis. At the two
follow-up visits (visits 2 and 3), KOH wet mount
and vaginal Candida culture were obtained. In ad-
dition, vulvovaginal signs and symptoms, concomi-
tant medication use, and adverse events were
monitored.
Cure Definitions
Clinical response was assessed at both follow-up
visits on the basis of presence or absence of vulvo-
vaginal signs/symptoms (e.g., burning, itching, er-
ythema, swelling, excoriation, and ulceration) rated
on a 4-point categorical scale (i.e., 0 none;
mild; 2 moderate; 3 severe). Clinical cure was
achieved when all of the following conditions were
met at a follow-up visit: all vulvovaginal sign and
symptom severity scores were 0 or 1; each of the
patient’s sign and symptom scores was not greater
(getting worse) than the score for the previous visit
(baseline or the first follow-up visit); and at least
half of the sign and symptom scores that were >
in the preceding visit (including baseline) im-
proved to scores of 0 or 1. There was one exception
to these guidelines: a patient was considered clini-
cally cured at the second follow-up visit if all as-
sessments at the first follow-up visit were 0 except
for one score of 1, and the assessments remained
the same at the second follow-up visit (with no
missing assessments at either visit). Patients not
clinically cured were considered clinical treatment
failures. Any patient who was not clinically cured at
the first follow-up visit was excluded from the clinical
cure rate analysis at the second follow-up visit.
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Assessment of microbiologic response was based
on results of fungal culture and KOH wet mount. A
patient was considered microbiologically cured if her
fungal culture was negative and her KOH wet
mount result was either negative or missing. Any
patient who was not microbiologically cured at the
first follow-up visit was excluded from the micro-
biological cure rate analysis at the second follow-up
visit.
Therapeutic cure was defined as clinical and mi-
crobiologic cures at both follow-up visits, and
therapeutic failure as either a clinical or a micro-
biologic failure at either follow-up visit. Patients
who were never clinical or microbiologic failures,
but who did not have all four cure rate results were
considered to have insufficient data for determina-
tion of their results. Therefore, their results were
considered missing, and they were excluded from
the therapeutic cure analysis, as well as from the
clinical or microbiologic cure analysis for that visit.
Statistical Analysis
Baseline comparability of the treatment groups was
assessed using a two-way analysis of variance
(ANOVA) with factors of treatment, investigator,
and treatment-by-investigator interaction for con-
tinuous variables and a Cochran-Mantel-Haenszel
test (controlling for investigator) for discrete vari-
ables. A significance level of 0.10 was used for
baseline treatment comparisons and for testing
treatment-by-investigator interaction.
The primary efficacy variables were the clinical
and microbiologic cure rates at each follow-up visit
and overall therapeutic cure rate. Valid follow-up
visits had to be within a 7 day to 15 post-treatment
day window for visit 2 and within a 27 day to 45
post-treatment day window for visit 3. Clinical and
microbiologic cure rates for each treatment group
were calculated at each follow-up visit by dividing
the number of cured patients by the total number
of patients analyzed. As an alternative, a more con-
servative procedure for the second follow-up visit
was also applied. This entailed counting patients as
failures if they were cured at the first follow-up
visit (visit 2) but had no results available from the
last visit (visit 3). Therapeutic cure rate was calcu-
lated by dividing the number of therapeutic cures
by the total number of patients analyzed, excluding
those who had insufficient data for this analysis.
Cure rates were analyzed as two independent
binomial proportions. Both a 95% two-tailed confi-
dence interval and a lower limits of 95% one-tailed
confidence interval for the difference in cure rates
(butoconazole minus miconazole) were calculated
using a normal approximation to the binomial dis-
tribution. Yate’s continuity correction was incorpo-
rated,s Cure rates for the two treatment groups
were also compared using the Cochran-Mantel-
Haenszel test for general association, controlling
for investigator,6 and a z-test that used the mini-
mum-variance estimator of the overall cure rate dif-
ferences across sites (butoconazole minus micona-
zole) in order to test the hypothesis that the treat-
ment difference was zero. 7
The use of these statistical analyses was justi-
fied by the assumption that there was no treat-
ment-by-investigator interaction (i.e., that data
from all sites could be pooled). This assumption
was tested by establishing the homogeneity of the
treatment odds ratios (butoconazole odds divided
by miconazole odds) across investigator sites us-
ing Zelen’s8 test and then testing that the common
odds ratio was equal to one,9 and by a chi-
square statistic that examined the homogeneity of
cure rate differences across the sites.7,1 Adverse
events were recorded and summarized using the
COSTART mapping system. 11
RESULTS
Nineteen investigators enrolled 403 patients, 5 of
whom did not receive the study medication after
enrollment, were not randomized, and were there-
fore excluded from all analyses. Thus, 398 patients
(199 in each treatment group) were randomly as-
signed to treatment with butoconazole nitrate
cream or miconazole nitrate cream. Nine patients
(2 butoconazole and 7 miconazole users) were lost
to follow-up and were excluded from the safety
analyses, which included 389 patients (197 buto-
conazole and 192 miconazole users). Included in
the efficacy analyses were 254 participants, com-
prising 119 butoconazole recipients and 135 mi-
conazole users. Exclusions from the efficacy analy-
ses are detailed in Table 1.
The treatment groups in the efficacy analyses
were comparable with respect to demographic
characteristics of age (mean 32 years, SD 10 years;
range 17-67 years), ethnicity (73% European, 15%
African American, 8% Latina, 3% Asian-American,
1% other), and height (mean 64.5 in., SD 2.8 in.;
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TABLE I. Patients excluded from efficacy analyses
Reason for exclusion Total (%) Butoconazole (%) Miconazole (%)
No confirmation that study drug was used
Negative or missing fungal culture/KOH*
Positive urine glucose or dysplasia on Pap smear
Non-compliance with study medication
Medication applied but no follow-up visits
First follow-up visit outside 7-15 day window
Used prohibited concomitant medication
Evidence of trichomonads, Gardnerella, bacterial vaginitis, or cervicitis
Total excluded**
Total included
Total enrolled, received study drug
9(2) 2(I) 7(4)
92(23) 53(27) 39(20)
4(I) 4(2) 0
14(3) 7(4) 7(4)
2(<1) 2(I) o
13(3) 7(4) 6(3)
2(<1) I(I) I(I)
8(2) 4(2) 4(2)
144(36) 80(40) 64(32)
254(64) II 9(60) 135(68)
398 199 199
*P 0.071 (Cochran-ManteI-Haenszel test).
**P 0.079 (Cochran-ManteI-Haenszel test).
range 51-72 in.). There were significant differ-
ences between the treatment groups in systolic
blood pressure (P 0.06), and there were signifi-
cant treatment-by-investigator interactions for
weight (P 0.003), systolic blood pressure (P
0.098), and diastolic blood pressure (P 0.053).
These variables were not considered to have an
impact on the cure rate outcomes. The groups were
comparable in baseline (pretreatment) signs of er-
ythema, ulceration, and presence and quantity of
discharge. There were significant differences be-
tween the groups in baseline vulvovaginal burning
(P 0.004) and itching (P 0.078), with a greater
proportion in the butoconazole group having severe
symptoms (burning: 19 patients [16%] for buto-
conazole and 8 patients [6%] for miconazole; itch-
ing: 34 patients [29%] for butoconazole and 26 pa-
tients [19%] for miconazole). Similarly, statistically
significant differences were also found for swelling
and excoriation at baseline (P 0.04 and 0.077,
respectively), and these significant differences in
baseline characteristics were due to a treatment-by-
investigator interaction, with most cases of swelling
or excoriation reported by only a few investigators.
When the Cochran-Mantel-Haenszel test was ap-
plied to the data collapsing on investigator, there
were no statistically significant differences (P >
0.197).
Efficacy
Cure rate data were pooled across all investigators
because the results of tests for homogeneity among
investigators showed no statistically significant
treatment-by-investigator interactions (Zelen’s test
P values 0.152-0.916; common odds ratios not
significantly different from and all 95% confi-
dence intervals for these ratios contained the value
1; and chi-square P values 0.152-0.514).
Clinical, microbiologic, and therapeutic cure
rates for butoconazole and miconazole were similar
between treatment groups, regardless of whether
patients with missing/insufficient data from the
second follow-up examination were excluded from
the analysis or included as treatment failures
(Table 2). No differences between butoconazole
nitrate and miconazole nitrate were statistically sig-
nificant. Clinical cure rates at the first follow-up
examination (approximately 8 days post-treatment)
were 92.4% for butoconazole and 94.8% for mi-
conazole; at the second follow-up assessment (ap-
proximately 30 days post-treatment), clinical cure
rates were 88.5% for butoconazole and 85.7% for
miconazole. Microbiologic cure rates at the first fol-
low-up visit were 88.1% for butoconazole and
89.6% for miconazole, and at the second follow-up
examination they were 75.5% and 78.4%, respec-
tively. An alternate procedure counted patients as
failures who were cured at the first follow-up visit
but missing their second follow-up data. This al-
ternate, more conservative procedure for estimat-
ing clinical and microbiologic cure rates resulted in
somewhat lower clinical cure rates at the second
follow-up visit (butoconazole: 77.3%; miconazole:
79.7%) and microbiologic cure rates (butoconazole:
68.3%; miconazole: 72.5%). Therapeutic cure rates
were 57.8% for butoconazole and 61.4% for mi-
conazole.
Eighteen patients, 11 in the butoconazole group
and 7 in the miconazole group, had fungal cultures
positive for organisms other than C. a/bicans. In the
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TABLE 2. Summary of cure rates
Cure rate
Treatment groups
Difference
Butoconazole Miconazole (%)
Two-sided 95%
confidence interval
(%)
First follow-up
Clinical
Microbiologic
Second follow-up
Clinical
Microbiologic
Therapeutic cure rate
I10/I 19 128/135
(92.4%) (94.8%) -2.4
104/I 18 120/I 34
(88.1%) (89.6%) -I.4
85/96 102/I 19
(88.5%) (85.7%) 2.8
71/94 87/I
(75.5%) (78.4%) -2.8
63/109 78/127
(57.8%) (61.4%) -3.6
-7.1, 12.7
-15.4, 9.7
-17, 9.8
aPatients with missing/insufficient data from the second follow-up visit were excluded from the analysis for that visit.
bButoconazole cure rate minus miconazole cure rate.
butoconazole group, 6 patients had Torulopsis gla-
brata, 2 had C. tropicalis, 2 C. parapsilosis, and
other non-albicans Candida. In the miconazole
group, 4 had T. glabrata, 1 C. stdlatoidea, C. parap-
silosis, and C. tropicalis. Therapeutic cures for bu-
toconazole recipients were achieved in 4 of the 9
patients valid for efficacy analysis, 2 with C. parap-
silosis, with C. tropicalis, and with T. glabrata. A
therapeutic cure was achieved in of the 5 micona-
zole users valid for efficacy analysis. This subject
had C. tropicalis. Four patients with fungal cultures
positive for non-albicans organisms were not ana-
lyzed (i.e., 2 treated with butoconazole nitrate and
2 with miconazolc nitrate).
SafeW
There were no deaths and no serious adverse
events reported. Three butoconazole-treated pa-
tients withdrew prematurely from the study be-
cause of non-serious adverse events: increased
burning and itching; vaginal burning; and itching
and rash. One miconazole user withdrew prema-
turely because of moderate lower abdominal
cramping. All of these events were considered
probably or possibly related to study medication.
Two patients withdrew prematurely because of
laboratory abnormalities (suspicious Pap smear
with dysplasia) and 5 because of intercurrent ill-
nesses (vaginal trichomoniasis, bladder pressure,
cervicitis, bacterial vaginitis, streptococcus group B
infection); these events were considered by the in-
vestigators to be probably not related to the study
medications.
Of all 389 patients evaluated in the safety analy-
sis, 148 (38%) reported a total of 287 adverse
events: 70 of 197 butoconazole recipients (36%)
and 78 of 192 miconazole users (41%). Overall for
both treatment arms, most adverse events (88%)
were rated as mild or moderate in severity and 67%
of all events were considered to be probably not
related to butoconazole nitrate or miconazole ni-
trate cream. The most commonly reported adverse
event was "headache" (butoconazole nitrate group:
9%; miconazole nitrate group: 9%).
Events related to the urogenital system were
reported by 60 patients (15%): 29 (15%) in the bu-
toconazole group and 31 (16%) in the miconazole
group. Urogenital complaints reported by more
than 3 patients were pain, pruritus, leukorrhea, and
vaginitis, as detailed in Table 3. Of the adverse
events considered by the investigators to be possi-
bly or probably related to study medications,
among the most frequently reported were vaginal
pain or itching, both of which were also symptoms
of the underlying disease.
DISCUSSION
The lack of statistically significant differences be-
tween the 3-day butoconazole regimen and the
7-day miconazole regimen with respect to micro-
biologic, clinical, or therapeutic cure rates coupled
with large sample sizes indicate that the two study
medications were equally effective in the treat-
ment of vulvovaginal candidiasis. Although the
study groups were demographically well matched,
clinical and therapeutic cure rate differences in this
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TABLE 3. Urogenital adverse events reported by
>3 patients
No. of patients reporting
Event Butoconazole Miconazole Total
Pain 15 13 28
Pruritus 12 9 21
Leukorrhea 6 7
Vaginitis 3 2 5
study may have been affected by the preponder-
ance of patients with severe itching or burning in
the butoconazole group (16% and 29%, respec-
tively, vs. 6% and 19%, respectively, for micona-
zole). Nonetheless, the study showed that both
drugs were equally effective in alleviating vaginitis
symptoms at visit 2, with continued or maintained
recovery at visit 3. Both study drugs were well tol-
erated, and no serious adverse events were re-
ported.
The findings of this study support those of
Kaufman et al., lz whose large-scale study also had
a randomized, investigator-blind design, and dem-
onstrated that 3-day butoconazole treatment was
equal in efficacy to 7-day miconazole therapy.
These authors speculated that the 3-day regimen
could have an advantage over the 7-day regimen in
that patients might be more likely to comply with
the full therapeutic regimen if given a shorter treat-
ment schedule.
Although the majority of patients in the present
study had fungal cultures positive for C. albicans, 18
patients had fungal cultures positive for organisms
other than C. albicans. Of the patients with non-
albicans species, therapeutic cures were achieved in
4 of 9 butoconazole users and of 5 miconazole
users. Two butoconazole patients were excluded
and 2 miconazole patients were excluded from
analysis. The sample in this subgroup was too small
to draw statistically significant or clinically relevant
conclusions. In a separate in vitro study, however,
butoconazole was found to be more effective at
lower concentrations than miconazole and other
azoles against non-a/bicans species,z In tests of 200
vaginal yeast isolates of 9 species, including 100
isolates of non-albicans species, Lynch and Sobelz
found only 2 isolates of C. bansei in which buto-
conazole >0.001 pg/ml was required to reduce mi-
croorganism growth by 80%. The minimal inhibi-
tory concentration of miconazole was 10-fold
higher than the butoconazole concentration in 173
isolates of C. albicans, C. glabrata, and C. parapsilo-
sis. Still higher concentrations of other azoles were
required for equivalent inhibitory effect.
CONCLUSIONS
Butoconazole nitrate 2% cream applied intravagi-
nally for 3 days and miconazole nitrate 2% cream
applied for 7 days demonstrated comparable effi-
cacy in the treatment of vulvovaginal candidiasis.
In addition, both treatments were well tolerated
and were not associated with any serious adverse
events. These results indicate that butoconazole
nitrate 2% cream, applied once daily for 3 days, is
comparable to an approved over-the-counter prod-
uct.
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